EP Patent

EP1910290A2 — Gpcr agonists

Assigned to Prosidion Ltd · Expires 2008-04-16 · 18y expired

What this patent protects

Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.

USPTO Abstract

Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.

Drugs covered by this patent

Patent Metadata

Patent number
EP1910290A2
Jurisdiction
EP
Classification
—
Expires
2008-04-16
Drug substance claim
No
Drug product claim
No
Assignee
Prosidion Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.